Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 19/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941029 | 0.91 | MME (0.48) | MMEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL16941439 | 0.89 | MME (0.67) | MME | |
| SCHEMBL16941516 | 0.87 | MME (0.45) | MMEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL16941161 | 0.86 | MME (0.45) | MMEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL18626433 | 0.83 | MME (0.51) | MME | |
| SCHEMBL16930520 | 0.79 | MME (0.55) | MME | |
| SCHEMBL20280997 | 0.79 | MME (0.55) | MME | |
| SCHEMBL16941449 | 0.79 | MME (0.55) | MME | |
| SCHEMBL16940986 | 0.79 | MME (0.55) | MME | |
| SCHEMBL18626455 | 0.79 | MME (0.56) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885KDM4E 2253/4885ALDH1A1 2612/4885 |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885KDM4E 2253/4885ALDH1A1 2612/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885KDM4E 2253/4885ALDH1A1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.